
<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>AGA Clinical Practice Guideline on the Prevention and Treatment of Hepatitis B Virus Reactivation in At-Risk Individuals  </title>
<style>

<style>
/* ===== GENERAL LAYOUT ===== */
body {
    font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
    background: linear-gradient(135deg, #eef2ff, #fafafa);
    color: #2c2c2c;
    padding: 30px;
    margin: 0;
}

/* Centered mindmap container */
.mindmap {
    max-width: 800px;
    margin: auto;
    font-size: 20px;
    line-height: 1.7;
}

/* ===== LISTS ===== */
.mindmap ul {
    margin: 0.6em 0 1em 1.5em;
    padding-left: 1.4em;
    list-style: disc;
    color: #555;
    font-size: 0.95em;
    font-weight: 400;
    line-height: 1.6;
}

.mindmap li::marker {
    color: #8b5cf6; /* accent bullet color */
}

.mindmap li {
    margin-bottom: 6px;
    padding-left: 4px;
}

/* ===== COLLAPSIBLE SECTIONS ===== */
.mindmap details {
    /* FIX: Increased border width and used a darker color */
    border-left: 5px solid #7c3aed; 
    background: #ffffff;
    margin: 8px 0;
    /* FIX: Corrected typo "20x" to "20px" */
    padding: 9px 25px; 
    border-radius: 20px;
    box-shadow: 0 4px 12px rgba(139, 92, 246, 0.1);
    transition: all 0.3s ease;
    position: relative;
}

/* Subsection (nested details) */
.mindmap details > div > details {
    margin-left: -8px;
    /* FIX: Used a darker, more saturated color for the nested border */
    border-color: #9333ea; 
    background: #faf7ff;
}

/* Subtle hover feedback */
.mindmap details:hover {
    box-shadow: 0 6px 18px rgba(139, 92, 246, 0.18);
    background: linear-gradient(135deg, #ffffff, #f5f0ff);
}

/* ===== SUMMARY HEADERS ===== */
.mindmap summary {
    cursor: pointer;
    font-size: 1.1em;
    font-weight: 600;
    list-style: none;
    position: relative;
    /* FIX: Increased padding slightly to prevent text from touching the arrow icon */
    padding-left: 24px; 
    color: #4c1d95;
    outline: none;
}

/* Custom arrow icon */
.mindmap summary::before {
    content: "▶";
    position: absolute;
    left: 0;
    top: 2px;
    transition: transform 0.3s ease;
    font-size: 1em;
    color: #7c3aed;
}

/* Rotated arrow when open */
.mindmap details[open] > summary::before {
    transform: rotate(90deg);
}

/* Section title emphasis */
.mindmap summary strong {
    display: block;
    font-size: 1.25em;
    color: #4c1d95;
}

.mindmap summary em {
    font-style: normal;
    color: #6b21a8;
    font-size: 0.95em;
}

/* Open section highlighting */
.mindmap details[open] > summary {
    background: #f3e8ff;
    border-radius: 8px;
    padding: 6px 10px;
}

/* Smooth fade for expanded content */
.mindmap details[open] > div {
    animation: fadeIn 0.3s ease-in;
}

/* ===== DESCRIPTION BOXES ===== */
.mindmap .desc-box {
    background: #fdfcff;
    border: 2px solid #e5d9fb;
    border-left: 4px solid #c084fc;
    padding: 6px 10px;
    margin: 12px 0 18px 0;
    border-radius: 12px;
    box-shadow: 0 1px 3px rgba(160, 104, 255, 0.05);
    transition: background 0.3s ease;
}
.mindmap .desc-box:hover {
    background: #f8f4ff;
}

/* ===== ANIMATIONS ===== */
@keyframes fadeIn {
    from { opacity: 0; transform: translateY(-3px); }
    to { opacity: 1; transform: translateY(0); }
}

/* ===== BUTTONS ===== */
button {
    background-color: #7c3aed;
    color: white;
    border: none;
    padding: 10px 16px;
    margin: 0 6px;
    font-size: 2em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
button:hover {
    background-color: #6b21a8;
    transform: scale(1.05);
}

/* ===== FLOATING CONTROL PANEL ===== */
#level-controls {
    position: fixed;
    bottom: 30px;
    left: 85%;
    transform: translateX(-50%);
    background: rgba(255, 255, 255, 0.05);
    padding: 10px 16px;
    border-radius: 12px;
    box-shadow: 0 4px 12px rgba(0, 0, 0, 0.15);
    z-index: 9999;
    backdrop-filter: blur(6px);
    cursor: move;
    display: flex;
    align-items: center;
    gap: 6px;
}

/* Buttons inside the panel */
#level-controls button {
    background-color: rgba(124, 58, 237, 0.85);
    color: white;
    border: none;
    padding: 8px 14px;
    font-size: 2em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
#level-controls button:hover {
    background-color: rgba(107, 33, 168, 0.95);
    transform: scale(1.05);
}

/* Search input inside panel */
#level-controls input {
    border: 1px solid #d5c4ff;
    border-radius: 8px;
    padding: 7px 10px;
    font-size: 0.95em;
    outline: none;
    width: 150px;
    transition: border-color 0.2s ease;
}
#level-controls input:focus {
    border-color: #8b5cf6;
}

/* Search count text */
#searchCount {
    margin-left: 8px;
    font-style: italic;
    color: #4c1d95;
    font-size: 0.9em;
}

/* ===== SEARCH HIGHLIGHT ===== */
mark.search-highlight {
    background-color: #fff59d;
    color: #000;
    border-radius: 3px;
    padding: 1px 3px;
}



/* ===== CLICK-TO-REVEAL: Spoiler Blur Style ===== */
.mindmap q {
    cursor: pointer;
    color: transparent;
    /* Apply a text-shadow with the same color as the text to create the blur effect */
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease;
}

.mindmap q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}

/* Style for the revealed text */
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}




/*for full control button*/
/* ===== CLICK-TO-REVEAL: Spoiler Blur Style (with Read Mode) ===== */

/* This rule applies the blur ONLY when the mindmap is NOT in read-mode. */
.mindmap:not(.read-mode) q {
    cursor: pointer;
    color: transparent;
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease, color 0.3s ease;
}

.mindmap:not(.read-mode) q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}

/* This combined rule handles BOTH cases for revealing text:
   1. The entire mindmap is in read-mode.
   2. An individual <q> has been clicked (in quiz mode).
*/
.mindmap.read-mode q,
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}


</style>

</style>
</head>
<body>

<!-- Updated Controls -->
<div id="level-controls" onmousedown="dragElement(this)">
    <button onclick="zoomIn()">+</button>
    <button onclick="zoomOut()">-</button>
    <button onclick="resetView()">=</button>
    <!-- NEW: READ MODE TOGGLE BUTTON -->
    <button onclick="toggleReadMode()">Q/R</button>
</div>

<div class="mindmap">
<div class="mindmap">
<details><summary><strong>AGA Clinical Practice Guideline on the Prevention and Treatment of Hepatitis B Virus Reactivation in At-Risk Individuals  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Source: AGA Institute, February 2025  </li>
<li style="margin-left: 0px;">Topic: Hepatitis B Reactivation Prevention and Treatment  </li>
</ul>
<details><summary><strong>Background &amp; Aims  </strong></summary><div style="padding-left: 20px;">
<details><summary><strong>Overview of HBV Reactivation:  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Hepatitis B virus reactivation (HBVr) occurs due to immune-modulating exposures, such as immunosuppressive therapies or disease states.  </li>
<li style="margin-left: 0px;">Baseline risk depends on serology status: HBsAg-positive vs anti-HBc–positive/HBsAg-negative.  </li>
</ul>
</div></details>
<details><summary><strong>Aim of Guideline:  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Update evidence-based recommendations for managing HBVr risk in at-risk individuals, incorporating new studies since the 2014 publication.  </li>
</ul>
</div></details>
<details><summary><strong>Key Objectives:  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Address various exposures, including immune checkpoint inhibitors (ICIs), anti-TNF therapies, and others.  </li>
<li style="margin-left: 0px;">Provide guidance on antiviral prophylaxis vs monitoring alone based on risk categories.  </li>
</ul>
</div></details>
</div></details>
<details><summary><strong>Methods  </strong></summary><div style="padding-left: 20px;">
<details><summary><strong>Framework Used:  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach to assess evidence quality.  </li>
</ul>
</div></details>
<details><summary><strong>Evidence Synthesis:  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Systematic review of studies since 2014, including randomized controlled trials (RCTs) and observational data.  </li>
<li style="margin-left: 0px;">Focus on critical outcomes like HBVr incidence, hepatitis flares, chemotherapy interruption, and adverse events.  </li>
</ul>
</div></details>
<details><summary><strong>Risk Categories:  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Defined low (&lt;1%), moderate (1%–10%), and high (&gt;10%) risk thresholds for HBVr.  </li>
<li style="margin-left: 0px;">These categories guide recommendations: strong for high-risk, conditional for moderate and low-risk scenarios.  </li>
</ul>
</div></details>
<details><summary><strong>Certainty Assessment:  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Effect estimates from pooled RRs, with concerns about imprecision limiting certainty in some cases.  </li>
<li style="margin-left: 0px;">Used GRADEpro software to evaluate evidence across domains like bias, inconsistency, and feasibility.  </li>
</ul>
</div></details>
<details><summary><strong>Other Considerations:  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Universal CDC screening guidance for HBV in adults aged ≥18 years.  </li>
<li style="margin-left: 0px;">Equity and cost-effectiveness analyses incorporated to inform recommendations.</li>
</ul>
</div></details>
</div></details>
<details><summary><strong>Recommendation 1: For individuals at high risk of HBVr, the AGA recommends antiviral prophylaxis over monitoring alone. (Strong recommendation, moderate certainty evidence)  </strong></summary><div style="padding-left: 20px;">
<details><summary><strong>Implementation Considerations:  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">This recommendation assumes the use of antivirals with a high barrier to resistance.  </li>
<li style="margin-left: 0px;">Antiviral prophylaxis should be started before the initiation of risk-imposing therapy and continued for at least 6 months after discontinuation (at least 12 months for B-cell depleting agents).  </li>
</ul>
</div></details>
</div></details>
<details><summary><strong>Recommendation 2: For individuals at moderate risk of HBVr, the AGA suggests antiviral prophylaxis over monitoring alone. (Conditional recommendation, moderate certainty evidence)  </strong></summary><div style="padding-left: 20px;">
<details><summary><strong>Implementation Considerations:  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">This recommendation assumes the use of antivirals with a high barrier to resistance.  </li>
<li style="margin-left: 0px;">Patients who prioritize avoiding long-term antiviral use or its costs may opt for monitoring, performed at 1- to 3-month intervals including viral load assessment.  </li>
</ul>
</div></details>
</div></details>
<details><summary><strong>Recommendation 3: For individuals at low risk of HBVr, the AGA suggests monitoring alone over using antiviral prophylaxis. (Conditional recommendation, moderate certainty evidence)  </strong></summary><div style="padding-left: 20px;">
<details><summary><strong>Implementation Considerations:  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">This recommendation assumes regular and sufficient follow-up for continued monitoring.  </li>
<li style="margin-left: 0px;">Patients may choose antiviral therapy if they value avoiding reactivation risks, despite the low baseline probability.  </li>
</ul>
</div></details>
</div></details>
<details><summary><strong>Recommendation 4: For individuals at potential risk of HBVr, the AGA recommends testing for hepatitis B. (Strong recommendation, moderate certainty evidence)  </strong></summary><div style="padding-left: 20px;">
<details><summary><strong>Implementation Considerations:  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Testing should follow CDC guidelines for universal screening in adults ≥18 years.  </li>
<li style="margin-left: 0px;">Initial serologic markers followed by viral load testing if positive or equivocal.  </li>
</ul>
</div></details>
</div></details>
<details><summary><strong>Risk Categories Summary:  </strong></summary><div style="padding-left: 20px;">
<details><summary><strong>High-Risk Exposures (Baseline risk &gt;10%):  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Anthracycline derivatives in HBsAg-positive patients.  </li>
<li style="margin-left: 0px;">B-cell depleting agents (rituximab, ofatumumab) in any serology status.  </li>
<li style="margin-left: 0px;">Anti-TNF therapy in HBsAg-positive patients.  </li>
</ul>
</div></details>
<details><summary><strong>Moderate-Risk Exposures (Baseline risk 1%–10%):  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Immune checkpoint inhibitors in HBsAg-positive patients.  </li>
<li style="margin-left: 0px;">Anti-TNF therapy in anti-HBc–positive/HBsAg-negative patients with moderate baseline risk.  </li>
<li style="margin-left: 0px;">CAR-T cell therapy in anti-HBc–positive/HBsAg-negative patients.  </li>
</ul>
</div></details>
<details><summary><strong>Low-Risk Exposures (Baseline risk &lt;1%):  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Methotrexate, 6-MP, azathioprine in anti-HBc–positive/HBsAg-negative patients.  </li>
<li style="margin-left: 0px;">Corticosteroid therapy (&lt;10 mg dose) in anti-HBc–positive/HBsAg-negative patients.  </li>
<li style="margin-left: 0px;">Low-dose corticosteroid therapy (&lt;10 mg) in anti-HBc–positive/HBsAg-negative patients.  </li>
</ul>
</div></details>
</div></details>
<details><summary><strong>Summary of Evidence:  </strong></summary><div style="padding-left: 20px;">
<details><summary><strong>Baseline Risk by Exposure:  </strong></summary><div style="padding-left: 20px;">
<table border="1" cellspacing="0" cellpadding="4">
<thead><tr>
<th>Exposure</th>
<th>High-Risk Baseline</th>
<th>Moderate/ Low-Risk Baseline</th>
</tr></thead>
<tbody>
<tr>
<td>Anthracycline derivatives</td>
<td>50 per 1000</td>
<td>&lt;0.1% (very low certainty)</td>
</tr>
<tr>
<td>B-cell depleting agents</td>
<td>&gt;500 per 1000</td>
<td>Very high certainty (&gt;90%)</td>
</tr>
<tr>
<td>Anti-TNF therapy</td>
<td>&gt;10% baseline risk</td>
<td>Moderate certainty, low events reported</td>
</tr>
<tr>
<td>Immune checkpoint inhibitors</td>
<td>High-risk category (&gt;10%)</td>
<td>Low certainty due to crossing thresholds</td>
</tr>
<tr>
<td>CAR-T cell therapy</td>
<td>High-risk category (&gt;10%)</td>
<td>Moderate certainty, low events reported</td>
</tr>
<tr>
<td>Methotrexate/6-MP/Azathioprine</td>
<td>Low-risk category (&lt;1%)</td>
<td>Conditional until studies verify these statements</td>
</tr>
<tr>
<td>Corticosteroids</td>
<td>Dose-dependent risk categories</td>
<td>Moderate certainty, low events reported</td>
</tr>
</tbody>
</table>
</div></details>
<details><summary><strong>Key Findings:  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">The baseline risk of HBVr varies significantly by exposure type and patient serology.  </li>
<li style="margin-left: 0px;">For high-risk exposures, antiviral prophylaxis reduces the risk of reactivation by approximately 82%.  </li>
<li style="margin-left: 0px;">For moderate-risk exposures, antiviral prophylaxis reduces the risk by approximately 72%.  </li>
<li style="margin-left: 0px;">For low-risk exposures, antiviral prophylaxis reduces the risk by approximately 50%.  </li>
</ul>
</div></details>
</div></details>
<details><summary><strong>Limitations and Gaps:  </strong></summary><div style="padding-left: 20px;">
<details><summary><strong>Uncertainty in Risk Categories:  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">The certainty of evidence for some risk categories is limited due to concerns about imprecision.  </li>
</ul>
</div></details>
<details><summary><strong>Need for Further Research:  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">More robust data is needed, particularly for exposures with very low baseline risk.  </li>
</ul>
</div></details>
<details><summary><strong>Practical Considerations:  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">The guideline acknowledges that long-term monitoring may not be feasible for all patients.  </li>
</ul>
</div></details>
</div></details>
<details><summary><strong>Conclusion:  </strong></summary><div style="padding-left: 20px;">
<details><summary><strong>Evidence Summary:  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">The panel found moderate certainty evidence supporting antiviral prophylaxis for high-risk patients.  </li>
</ul>
</div></details>
<details><summary><strong>Clinical Recommendations:  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Use preemptive antiviral prophylaxis for high-risk exposures.  </li>
</ul>
</div></details>
<details><summary><strong>Monitoring Strategy:  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">For moderate and low-risk patients, implement a structured monitoring plan with clear intervals.</li>
</ul>
</div></details>
</div></details>
</div></details>
</div>
</div>

<br>
<br>
<br>
<br>
<br>


<script>
// --- State Management for Expansion Level ---
let currentLevel = 1; 
const maxLevel = 10;
const minLevel = 1;

// --- Core Function to Set Mindmap Expansion ---
function setMindmapLevel(level) {
    const allDetails = document.querySelectorAll('.mindmap details');
    allDetails.forEach(detail => detail.removeAttribute('open'));
    allDetails.forEach(detail => {
        let depth = 0;
        let parent = detail.parentElement;
        while (parent && parent.tagName !== 'BODY') {
            if (parent.tagName === 'DETAILS') {
                depth++;
            }
            parent = parent.parentElement;
        }
        if (depth < level) {
            detail.setAttribute('open', '');
        }
    });
}

// --- Control Functions ---
function zoomIn() {
    if (currentLevel < maxLevel) {
        currentLevel++;
        setMindmapLevel(currentLevel);
    }
}

function zoomOut() {
    if (currentLevel > minLevel) {
        currentLevel--;
        setMindmapLevel(currentLevel);
    }
}

function resetView() {
    currentLevel = minLevel;
    setMindmapLevel(currentLevel);
}


// --- NEW: Function to Toggle Read/Quiz Mode ---
function toggleReadMode() {
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.classList.toggle('read-mode');
    }
}

// --- Draggable Controls ---
function dragElement(elmnt) {
    let pos1 = 0, pos2 = 0, pos3 = 0, pos4 = 0;
    const onMouseDown = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos3 = e.clientX;
        pos4 = e.clientY;
        document.onmouseup = closeDragElement;
        document.onmousemove = elementDrag;
    };
    const elementDrag = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos1 = pos3 - e.clientX;
        pos2 = pos4 - e.clientY;
        pos3 = e.clientX;
        pos4 = e.clientY;
        elmnt.style.top = (elmnt.offsetTop - pos2) + "px";
        elmnt.style.left = (elmnt.offsetLeft - pos1) + "px";
        elmnt.style.transform = "none";
        elmnt.style.bottom = "auto";
    };
    const closeDragElement = () => {
        document.onmouseup = null;
        document.onmousemove = null;
    };
    if (document.getElementById(elmnt.id)) {
        document.getElementById(elmnt.id).onmousedown = onMouseDown;
    } else {
        elmnt.onmousedown = onMouseDown;
    }
}




// --- Initial Setup ---
window.addEventListener('DOMContentLoaded', () => {
    // Set the initial mindmap view
    setMindmapLevel(currentLevel);

    // Get the draggable controls element
    const controls = document.getElementById('level-controls');
    if (controls) {
        dragElement(controls);
    }

    // --- CORRECTED & IMPROVED: Setup for Click-to-Reveal ---
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.addEventListener('click', function(event) {
            // Use .closest() to find the nearest parent <q> tag.
            // This is more robust than checking event.target.tagName.
            const quoteElement = event.target.closest('q');
            
            if (quoteElement) {
                // Add the 'is-revealed' class to show the text
                quoteElement.classList.add('is-revealed');
            }
        });
    }
});
</script>

</body>
</html>
